Long-term outcome of postoperative irradiation in patients with newly diagnosed WHO grade III anaplastic gliomas

Tumori

Volumn 95, Issue 3, 2009, Pages 317-324

  Nagy, Monika ^a   Schulz Ertner, Daniela ^a   Bischof, Marc ^a   Welzel, Thomas ^a   Hof, Holger ^a   Debus, Jürgen ^a   Combs, Stephanie E ^a,b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Astrocytoma; Glioma; Outcome; Radiotherapy

Indexed keywords

ADULT; ANAPLASTIC CARCINOMA; ARTICLE; ASTROCYTOMA; BIOPSY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURGERY; FOLLOW UP; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; IRRADIATION; MAJOR CLINICAL STUDY; MIXED TUMOR; OLIGODENDROGLIOMA; OVERALL SURVIVAL; POSTOPERATIVE CARE; PROGRESSION FREE SURVIVAL; SURVIVAL TIME;

ASTROCYTOMA; CONVENTIONAL FRACTIONATIONS; GLIOMA; LONG-TERM OUTCOME; OUTCOME; POSTOPERATIVE RADIOTHERAPY; PROGRESSION FREE SURVIVAL; RADIOCHEMOTHERAPY;

BIOPSY; RADIOTHERAPY;

TUMORS;

EID: 67849103453     PISSN: 03008916     EISSN: None     Source Type: Journal    
DOI: 10.1177/030089160909500308     Document Type: Article

References (62)

1. Burger PC, Vogel FS, Green SB, Strike TA: Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer, 56: 1106-1111, 1985.
2. Kleihues P, Soylemezoglu F, Schauble B, Scheithauer BW, Burger PC: Histopathology, classification, and grading of gliomas. Glia, 15: 211-221, 1995.
3. Kleihues P, Burger PC, Scheithauer BW: The new WHO classification of brain tumours. Brain Pathol, 3: 255-268, 1993. (Pubitemid 23276692)
4. Kleihues P, Sobin LH: World Health Organization classification of tumors. Cancer, 88: 2887, 2000. (Pubitemid 30417954)
5. See SJ, Gilbert MR: Anaplastic astrocytoma: diagnosis, prognosis, and management. Semin Oncol, 31: 618-634, 2004.
6. Walker MD, Strike TA, Sheline GE: An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol.
7. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey JJr, Owens G, Ransohoff J, Robertson JT, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med, 303: 1323-1329, 1980.
8. Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg, 49: 333-343, 1978.
9. Kristiansen K, Hagen S, Kollevold T, Torvik A, Holme I, Nesbakken R, Hatlevoll R, Lindgren M, Brun A, Lindgren S, Notter G, Andersen AP, Eigen K: Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer, 47: 649-652, 1981.
10. Bauman GS, Ino Y, Ueki K, Zlatescu MC, Fisher BJ, Macdonald DR, Stitt L, Louis DN, Cairncross JG: Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys, 48: 825-830, 2000.
11. Cairncross JG, Ueki K, Zlatescu MC, Lisle DK, Finkelstein DM, Hammond RR, Silver JS, Stark PC, Macdonald DR, Ino Y, Ramsay DA, Louis DN: Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst, 90: 1473-1479, 1998. (Pubitemid 28482012)
12. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Nelson DF, Fischbach AJ, Chang CH, Rotman M, Asbell SO: Does extent of surgery influence outcome for astrocytoma with atypical or anaplastic foci (AAF)? A report from three Radiation Therapy Oncology Group (RTOG) trials. J Neurooncol, 12: 219-227, 1992.
13. Nitta T, Sato, K: Prognostic implications of the extent of surgical resection in patients with intracranial malignant gliomas. Cancer, 75: 2727-2731, 1995.
14. Gaspar LE, Fisher BJ, Macdonald DR, LeBer DV, Halperin EC, Schold SC Jr, Cairncross JG: Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys, 24: 55-57, 1992.
15. Hochberg FH, Pruitt A: Assumptions in the radiotherapy of glioblastoma. Neurology, 30: 907-911, 1980.
16. Liang BC, Thornton AF Jr, Sandler HM, Greenberg HS: Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. J Neurosurg, 75: 559-563, 1991.
17. Clark TG, Bradburn MJ, Love SB, Altman DG: Survival analysis part I: basic concepts and first analyses. Br J Cancer, 89: 232-238, 2003.
18. Bradburn MJ, Clark TG, Love SB, Altman DG: Survival analysis part III: multivariate data analysis - choosing a model and assessing its adequacy and fit. Br J Cancer, 89: 605-611, 2003.
19. Bradburn MJ, Clark TG, Love SB, Altman DG: Survival analysis part II: multivariate data analysis - an introduction to concepts and methods. Br J Cancer, 89: 431-436, 2003. (Pubitemid 37026422)
20. Hess KR: Extent of resection as a prognostic variable in the treatment of gliomas. J Neurooncol, 42: 227-231, 1999. (Pubitemid 29322199)
21. Vuorinen V, Hinkka S, Farkkila M, Jaaskelainen J: Debulking or biopsy of malignant glioma in elderly people - a randomised study. Acta Neurochir (Wien), 145: 5-10, 2003. (Pubitemid 36174074)
22. Tortosa A, Vinolas N, Villa S, Verger E, Gil JM, Brell M, Caral L, Pujol T, Acebes JJ, Ribalta T, Ferrer I, Graus F: Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer, 97: 1063-1071, 2003. (Pubitemid 36173159)
23. Cohen ZR, Shi W, Weinberg JS: Surgical resection of anaplastic astrocytoma: prognostic factors and outcome (Abstract). Neurooncology, 4: 367, 2002.
24. Laws ER, Shaffrey ME, Morris A: Surgical management of intracranial gliomas - Does radical resection imrove outcome? Acta Neurochir, 85 (suppl): 47-53, 2003.
25. Oppitz U, Maessen D, Zunterer H, Richter S, Flentje M: 3D-recurrence-patterns of glioblastomas after CT-planned postoperative irradiation. Radiother Oncol, 53: 53-57, 1999.
26. Lee SW, Fraass BA, Marsh LH, Herbort K, Gebarski SS, Martel MK, Radany EH, Lichter AS, Sandler HM: Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int J Radiat Oncol Biol Phys, 43: 79-88, 1999.
27. Medical Research Council Brain Tumor Working Party: Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. J Clin Oncol, 19: 509-518, 2001.
28. CBTRUS: Statistical report: Primary brain tumors in the United States 1995-1999. Central Brain Tumor Registry of the United States, Chicago, IL, 2002.
29. Werner-Wasik M, Scott CB, Nelson DF, Gaspar LE, Murray KJ, Fischbach JA, Nelson JS, Weinstein AS, Curran WJ Jr: Final report of a phase I/II trial of hyperfractionated and accelerated hyperfractionated radiation therapy with carmustine for adults with supratentorial malignant gliomas. Radiation Therapy Oncology Group Study 83-02. Cancer, 77: 1535-1543, 1996.
30. Prados MD, Wara WM, Sneed PK, McDermott M, Chang SM, Rabbitt J, Page M, Malec M, Davis RL, Gutin PH, Lamborn K, Wilson CB, Phillips TL, Larson DA: Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys, 49: 71-77, 2001. (Pubitemid 32041278)
31. Levin VA, Maor MH, Thall PF, Yung WK, Bruner J, Sawaya R, Kyritsis AP, Leeds N, Woo S, Rodriguez L: Phase II study of accelerated fractionation radiation therapy with carboplatin followed by vincristine chemotherapy for the treatment of glioblastoma multiforme. Int J Radiat Oncol Biol Phys, 33: 357-364, 1995.
32. Fernandez PM, Zamorano L, Yakar D, Gaspar L, Warmelink C: Permanent iodine-125 implants in the up-front treatment of malignant gliomas. Neurosurgery, 36: 467-473, 1995.
33. Laperriere NJ, Leung PM, McKenzie S, Milosevic M, Wong S, Glen J, Pintilie M, Bernstein M: Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys, 41: 1005-1011, 1998. (Pubitemid 28377480)
34. Stea B, Rossman K, Kittelson J, Shetter A, Hamilton A, Cassady IR: Interstitial irradiation versus interstitial thermoradiotherapy for supratentorial malignant gliomas: a comparative survival analysis. Int J Radiat Oncol Biol Phys, 30: 591-600, 1994. (Pubitemid 24304470)
35. Sneed PK, Lamborn KR, Larson DA, Prados MD, Malec MK, McDermott MW, Weaver KA, Phillips TL, Wara WM, Gutin PH: Demonstration of brachytherapy boost dose-response relationships in glioblastoma multiforme. Int J Radiat Oncol Biol Phys, 35: 37-44,1996.
36. Sneed PK, Stauffer PR, McDermott MW, Diederich CJ, Lamborn KR, Prados MD, Chang S, Weaver KA, Spry L, Malec MK, Lamb SA, Voss B, Davis RL, Wara WM, Larson DA, Phillips TL, Gutin PH: Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys, 40: 287-295, 1998. (Pubitemid 28114370)
37. Lutterbach J, Weigel P, Guttenberger R, Hinkelbein W: Accelerated hyperfractionated radiotherapy in 149 patients with glioblastoma multiforme. Radiother Oncol, 53: 49-52, 1999.
38. Gene M, Zorlu AF, Atahan IL: Accelerated hyperfractionated radiotherapy in supratentorial malignant astrocytomas. Radiother Oncol, 56: 233-238, 2000.
39. Nelson DF, Diener-West M, Horton J, Chang CH, Schoenfeld D, Nelson JS: Combined modality approach to treatment of malignant gliomas - re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. NCI Monogr, 279-284, 1988.
40. Brada M, Sharpe G, Rajan B, Britton J, Wilkins PR, Guerrero D, Hines F, Traish D, Ashley S: Modifying radical radiotherapy in high grade gliomas; shortening the treatment time through acceleration. Int J Radiat Oncol Biol Phys, 43: 287-292, 1999. (Pubitemid 29091466)
41. Jeremic B, Shibamoto Y, Grujicic D, Stojanovic M, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J: Concurrent accelerated hyperfractionated radiation therapy and carboplatin/etoposide in patients with malignant glioma: long-term results of a phase II study. J Neurooncol, 51:133-141, 2001. (Pubitemid 32435494)
42. Goffman TE, Dachowski LJ, Bobo H, Oldfield EH, Steinberg SM, Cook J, Mitchell JB, Katz D, Smith R, Glatstein E: Long-term follow-up on National Cancer Institute Phase I/II study of glioblastoma multiforme treated with iododeoxyuridine and hyperfractionated irradiation. J Clin Oncol, 10: 264-268, 1992.
43. Nelson DF, Diener-West M, Weinstein AS, Schoenfeld D, Nelson IS, Sause WT, Chang CH, Goodman R, Carabell S: A randomized comparison of misonidazole sensitized radiotherapy plus BCNU and radiotherapy plus BCNU for treatment of malignant glioma after surgery: final report of an RTOG study. Int J Radiat Oncol Biol Phys, 12: 1793 - 1800, 1986. (Pubitemid 17182219)
44. Prados MD, Scott C, Sandler H, Buckner JC, Phillips T, Schultz C, Urtasun R, Davis R, Gutin P, Cascino TL, Greenberg HS, Curran WJ Jr: A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404. Int J Radiat Oncol Biol Phys, 45: 1109-1115, 1999.
45. Peterson K, Harsh G, Fisher PG, Adler J, Le Q: Daily low-dose carboplatin as a radiation sensitizer for newly diagnosed malignant glioma. J Neurooncol, 53: 27-32, 2001. (Pubitemid 32936656)
46. Rao RD, Krishnan S, Fitch TR, Schomberg PJ, Dinapoli RP, Nordstrom K, Scheithauer B, O'Fallon JR, Maurer MJ, Buckner JC: Phase II trial of carmustine, cisplatin, and oral etoposide chemotherapy before radiotherapy for grade 3 astrocytoma (anaplastic astrocytoma): results of North Central Cancer Treatment Group trial 98-72-51. Int J Radiat Oncol Biol Phys, 61: 380-386, 2005. (Pubitemid 40164430)
47. Dillman RO, Shea WM, Tai DF, Mahdavi K, Barth NM, Kharkar BR, Poor MM, Church CK, DePriest C: Interferon-alpha2a and 13-cis-retinoic acid with radiation treatment for high-grade glioma. Neuro Oncol, 3: 35-41, 2001. (Pubitemid 33685584)
48. Buckner JC, Schomberg PJ, McGinnis WL, Cascino TL, Scheithauer BW, O'fallon JR, Morton, RF, Kuross SA, Mailliard JA, Hatfield AK, Cole JT, Steen PD, Bernath AM: A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma. Cancer, 92: 420-433, 2001.
49. Cairncross G, MacDonald D, Ludwin S, Lee D, Cascino T, Buckner J, Fulton D, Dropcho E, Stewart D, Schold C Jr: Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol, 12: 2013-2021, 1994.
50. Dehghani F, Schachenmayr W, Laun A, Korf HW: Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases. Acta Neuropathol (Berl), 95: 493-504, 1998.
51. Daumas-Duport C, Tucker ML, Kolles H, Cervera P, Beuvon F, Varlet P, Udo N, Koziak M, Chodkiewicz JP: Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria. J Neurooncol, 34: 61-78, 1997. (Pubitemid 27270252)
52. Schiffer D, Dutto A, Cavalla P, Bosone I, Chio A, Villani R, Bellotti C: Prognostic factors in oligodendroglioma. Can J Neurol Sci, 24: 313-319, 1997.
53. Cairncross JG, Macdonald DR: Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol, 23: 360-364, 1988.
54. Paleologos NA, Macdonald DR, Vick NA, Cairncross JG: Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma. Neurology, 53: 1141-1143, 1999.
55. Cairncross G, Seiferheld W, Shaw E: An intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas. Initial report of RTOG 9402. J Clin Oncol, 22: 107s, 2004.
56. Cairncross G, Seiferheld W, Shaw E: Intergroup randomized controlled clinical trial (RCT) of chemotherapy plus radiotherapy (RT) versus RT alone for pure and mixed anaplastic oligodendroglioma: Initial report of RTOG 94-02. Presented at the Society of Neuro-Oncology 9th Annual Scientific Meeting, Toronto, Canada. November 18-21, 2004.
57. van den Bent MJ, Chinot O, Boogerd W, Bravo MJ, Taphoorn MJ, Kros JM, van der Rijt CC, Vecht CJ, De Beule N, Baron B: Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol, 14: 599-602, 2003. (Pubitemid 41295090)
58. van den Bent MJ, Delattre JY, Brandes AA: First analysis of EORTC trial 26951, a randomized phase III study of adjuvant PCV chemotherapy in patients with highly anaplastic oligodendroglioma. Presented at the American Society of Clinical Oncology 41st Annual Meeting, Orlando, FL, May 13-17, 2005.
59. van den Bent MJ, Taphoorn MJ, Brandes AA, Menten J, Stupp R, Frenay M, Chinot O, Kros JM, van der Rijt CC, Vecht C, Allgeier A, Gorlia T: Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol, 21: 2525-2528, 2003. (Pubitemid 46606334)
60. van den Bent MJ, Keime-Guibert F, Brandes AA, Taphoorn MJ, Kros JM, Eskens FA, Carpentier AF: Temozolomide chemotherapy in recurrent oligodendroglioma. Neurology, 57: 340-342, 2001.
61. Lebrun C, Fontaine D, Ramaioli A, Vandenbos F, Chanalet S, Lonjon M, Michiels JF, Bourg, V, Paquis P, Chatel M, Frenay M: Long-term outcome of oligodendrogliomas. Neurology, 62: 1783-1787, 2004.
62. Vogelbaum M, Berkey B, Peereboom D, Giannini D, Suh J, Brown P, Blumenthal D, Biggs C, Schultz C, Mehta M: Phase II trial of pre-irradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligodendrogliomas. J Clin Oncol, 23: 119s (abstr 1520), 2005.